在妇科癌症进展和耐药性的ceRNA网络
Shuqin Wu1, Baoshan Zhong1, Yuxin Yang1
1Jiangxi Medical College, Nanchang University, Nanchang, China.
Journal of drug targeting
|September 19, 2023
概括
竞争的内源RNAs (ceRNAs) 在妇科癌症的进展和耐药性方面至关重要. 本综述探讨了ceRNAs作为潜在的治疗点和预测生物标志物,以改善诊断和治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 妇科癌症是全世界妇女的重大健康负担.
- 目前的诊断方法经常面临延迟和错误诊断,原因是对癌症发展的不完全理解和缺乏特定生物标志物的缺乏.
- 涉及竞争的内源RNA (ceRNA) 的微RNA (miRNA) 中介机制越来越多地被认为是它们在癌症中的作用.
研究的目的:
- 审查ceRNA假设对妇科癌症进展和耐药性的参与.
- 识别潜在的ceRNAs,可以作为治疗点.
- 探索ceRNAs作为妇科恶性瘤预测生物标记物的实用性.
主要方法:
- 关于竞争性内源RNAs (ceRNAs) 和妇科癌症的综合文献搜索.
- 对研究 miRNA 中介基因调节中 ceRNA 网络的研究进行分析.
- 综合证据,将ceRNA与癌症进展,治疗耐药性和诊断潜力联系起来.
主要成果:
- 在妇科癌症中,ceRNAs在调节各种癌症相关途径的基因表达中发挥着重要作用.
- 这些恶性瘤的发病和进展都与ceRNA网络的失调有关.
- 特定的ceRNA已经显示出影响治疗反应和疾病结果的潜力.
结论:
- ceRNA网络是妇科癌症的关键调节机制.
- 向ceRNAs提供了一个有前途的治疗策略,以克服治疗耐药性.
- ceRNAs具有作为早期诊断和妇科癌症预后的有价值生物标志物的潜力.
更多相关视频
相关概念视频
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Cancer Survival Analysis
381
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
381
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K


